Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis: Results From the Randomized Phase 2 Vivacity-MG Study
Carlo AntozziJeffrey T GuptillVera BrilJosep GamezSven Guenther MeuthRichard J NowakDianna QuanTeresa SevillaMarie-Helene JouvinJim JinKeith KarcherSindhu RamchandrenHong SunLeona LingYaowei ZhuSantiago Arroyonull nullPublished in: Neurology (2023)
This study provides Class I evidence that for patients with gMG, nipocalimab was well-tolerated, and it did not significantly improve MG-ADL at any individual dose but demonstrated a significant dose response for improved MG-ADL across doses.